Lattice Biologics (TSXV:LBL.H) Interest Expense : C$-0.75 Mil (TTM As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lattice Biologics's interest expense for the three months ended in Jun. 2021 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2021 was C$-0.75 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lattice Biologics's Operating Income for the three months ended in Jun. 2021 was C$ -0.03 Mil. Lattice Biologics's Interest Expense for the three months ended in Jun. 2021 was C$ 0.00 Mil. Lattice Biologics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Lattice Biologics Interest Expense Historical Data

The historical data trend for Lattice Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Interest Expense Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Interest Expense

Get a 7-Day Free Trial

-1.37

-0.57

-0.61

-0.72

-1.38

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Interest Expense	Get a 7-Day Free Trial															-0.14	-0.61	-0.15	-	-

Lattice Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.75 Mil.

Lattice Biologics (TSXV:LBL.H) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lattice Biologics's Interest Expense for the three months ended in Jun. 2021 was C$0.00 Mil. Its Operating Income for the three months ended in Jun. 2021 was C$-0.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2021 was C$0.00 Mil.

Lattice Biologics's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

Lattice Biologics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines